RU2006114743A - Композиция корма для животных - Google Patents
Композиция корма для животных Download PDFInfo
- Publication number
- RU2006114743A RU2006114743A RU2006114743/13A RU2006114743A RU2006114743A RU 2006114743 A RU2006114743 A RU 2006114743A RU 2006114743/13 A RU2006114743/13 A RU 2006114743/13A RU 2006114743 A RU2006114743 A RU 2006114743A RU 2006114743 A RU2006114743 A RU 2006114743A
- Authority
- RU
- Russia
- Prior art keywords
- iaa
- derivative
- composition according
- animal
- feed composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Insects & Arthropods (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
Claims (18)
1. Композиция корма для животных, содержащая более 240 мкг свободной IAA (индолилуксусной кислоты) или ее производного на килограмм, в которой указанное производное выбирается из группы, состоящей из 4-гидрокси-IAA, 4-метокси-IAA, 5-гидрокси-IAA, 5-метокси-IAA, 6-гидрокси-IAA, 6-метокси-IAA, 7-гидрокси-IAA, 7-метокси-IAA и соединения, которое может превращаться в свободную IAA в 3, предпочтительно в 2 и более предпочтительно в 1 стадию.
2. Композиция корма по п.1, содержащая до 40 г свободной IAA или ее производного на килограмм.
3. Композиция корма по п.1, содержащая от 100 до 1000 мг свободной IAA или ее производного на килограмм.
4. Композиция корма по п.1, дополнительно содержащая фермент, способный превращать производное IAA в свободную IAA.
5. Композиция корма по п.4, содержащая ароматическое кольцо, в которой ароматическое кольцо в одном или более из 4, 5, 6 и 7 положений замещается метилом, амино, нитро, фторидом, хлоридом, бромидом или йодидом.
6. Композиция корма по любому из пп.1-5 в форме пеллетов, муки, зерен, экструдированных или воздушных зерен, таблеток, порошка или пилюль.
7. Способ увеличения скорости роста и/или улучшения эффективности корма и/или скорости конверсии корма и/или иммунитета животного, не относящегося к человеческому роду, включающий скармливание указанному животному эффективного количества композиции по любому из пп.1-6.
8. Применение свободной IAA или ее производного, в котором указанное производное выбирается из группы, состоящей из 4-гидрокси-IAA, 4-метокси-IAA, 5-гидрокси-IAA, 5-метокси-IAA, 6-гидрокси-IAA, 6-метокси-IAA, 7-гидрокси-IAA, 7-метокси-IAA и соединения, которое может превращаться в свободную IAA в 3, предпочтительно в 2 и более предпочтительно в 1 стадию, для приготовления лечебной композиции для стимуляции иммунной системы у животных, не относящихся к человеческому роду, при необходимости проведения такого лечения.
9. Применение по п.8, в котором свободная IAA или ее производное способны повысить уровень инсулиноподобного фактора роста 1 (IGF-1) в сыворотке крови.
10. Применение по п.8, в котором животное имеет пониженный уровень IGF-1.
11. Применение по любому из пп.8-10, в котором животные имеют дефицит роста и/или ослабленную иммунную систему.
12. Применение композиции по любому из пп.1-6 для приготовления лечебной композиции для стимуляции роста и/или стимуляции иммунной системы у животных при необходимости проведения такого лечения.
13. Применение по п.12, в котором свободная IAA или ее производное способны повысить уровень инсулиноподобного фактора роста 1 (IGF-1) в сыворотке крови.
14. Применение по п.12, в котором животное имеет пониженный уровень IGF-1.
15. Применение по любому из пп.12-14, в котором животные имеют дефицит роста и/или ослабленную иммунную систему.
16. Способ приготовления композиции корма для животного, включающий смешивание композиции по любому из пп.1-6 с одним или более веществом (-ами) или ингредиентом (-ами) корма для получения композиции корма для животного по любому из пп.1-6.
17. Способ приготовления композиции корма для животного, включающий стадию добавления в корм для животного свободной IAA или ее производного для получения композиции корма для животного по любому из пп.1-6.
18. Способ выращивания животных, не относящихся к человеческому роду, включающий а) смешивание эффективной дозы свободной IAA или ее производного с кормовым материалом с целью получения композиции корма по любому из пп.1-6, пригодной для конкретных видов животных, б) кормление указанных видов животных кормовым материалом.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP03/11171 | 2003-10-03 | ||
PCT/EP2003/011171 WO2005039546A2 (en) | 2003-10-03 | 2003-10-03 | Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006114743A true RU2006114743A (ru) | 2007-11-10 |
RU2345552C2 RU2345552C2 (ru) | 2009-02-10 |
Family
ID=34429223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006114743/13A RU2345552C2 (ru) | 2003-10-03 | 2004-09-28 | Композиция корма для животных |
Country Status (16)
Country | Link |
---|---|
US (2) | US9408405B2 (ru) |
EP (1) | EP1670444B1 (ru) |
JP (1) | JP4641942B2 (ru) |
CN (1) | CN1938018B (ru) |
AT (1) | ATE506948T1 (ru) |
AU (1) | AU2003273967A1 (ru) |
CA (1) | CA2541090C (ru) |
CY (1) | CY1116665T1 (ru) |
DE (1) | DE60336934D1 (ru) |
DK (1) | DK1670444T3 (ru) |
ES (2) | ES2365847T3 (ru) |
HK (1) | HK1103963A1 (ru) |
PT (2) | PT1670444E (ru) |
RU (1) | RU2345552C2 (ru) |
SI (1) | SI1670444T1 (ru) |
WO (1) | WO2005039546A2 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10716778B2 (en) | 2003-10-03 | 2020-07-21 | Veijlen | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1667678T3 (da) | 2003-10-03 | 2009-08-24 | Veijlen N V | Dyrefodersammensætning |
JPWO2005049006A1 (ja) * | 2003-11-21 | 2007-11-29 | 味の素株式会社 | 糖尿病治療剤 |
PL2118123T3 (pl) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilizowane peptydy p53 i ich zastosowania |
EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
US9063122B2 (en) * | 2008-10-17 | 2015-06-23 | Alfredo Gallegos | Biomodulators for treatment or prevention of disease |
KR101810698B1 (ko) | 2009-06-11 | 2018-01-25 | 디에스엠 아이피 어셋츠 비.브이. | 근육 자극제로서의 니아신 및/또는 트라이고넬린 |
US9790186B2 (en) | 2009-07-21 | 2017-10-17 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
CN108570097A (zh) | 2010-08-13 | 2018-09-25 | 爱勒让治疗公司 | 拟肽大环化合物 |
JP6342808B2 (ja) | 2011-10-18 | 2018-06-13 | エイルロン セラピューティクス,インコーポレイテッド | ペプチドミメティック大環状化合物 |
RU2642299C2 (ru) | 2012-02-15 | 2018-01-24 | Эйлерон Терапьютикс, Инк. | P53 пептидомиметические макроциклы |
JP6450192B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス,インコーポレイテッド | トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物 |
SG11201503052RA (en) | 2012-11-01 | 2015-05-28 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof |
US10004718B2 (en) | 2012-11-26 | 2018-06-26 | Tohoku University | Erythropoietin expression promoter |
RU2524634C1 (ru) * | 2013-06-25 | 2014-07-27 | Государственное научное учреждение Северо-Кавказский зональный научно-исследовательский ветеринарный институт (ГНУ СКЗНИВИ) Российской академии сельскохозяйственных наук | Способ стимуляции роста птицы |
WO2015095650A1 (en) * | 2013-12-19 | 2015-06-25 | Puretein Bioscience Llc. | Methods for treating an animal |
KR102265412B1 (ko) * | 2014-08-13 | 2021-06-14 | 주식회사 엘지생활건강 | 그라민 또는 이의 약학적으로 허용가능한 염을 포함하는 피부 미백, 탄력, 주름개선, 보습 또는 항염증용 화장료 또는 약학 조성물 |
US10471120B2 (en) | 2014-09-24 | 2019-11-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
WO2016100528A1 (en) * | 2014-12-16 | 2016-06-23 | Puretein Bioscience Llc. | Methods for increasing serum igf-1 in an animal |
US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
WO2017035288A1 (en) * | 2015-08-27 | 2017-03-02 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
US11701348B1 (en) | 2016-07-23 | 2023-07-18 | Turtle Bear Holdings, Llc | Psilocybin compositions |
US20210069170A1 (en) | 2016-07-23 | 2021-03-11 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
AU2019398016A1 (en) * | 2018-12-13 | 2021-07-22 | Aim Immunotech Inc. | Methods for improving exercise tolerance in myalgic encephalomyelitis patients |
WO2020212951A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
CN111407884B (zh) * | 2019-06-24 | 2021-12-07 | 浙江大学 | 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途 |
US20210077591A1 (en) * | 2019-09-09 | 2021-03-18 | The University Of Chicago | Combination therapy for the treatment of migraines |
IL291839A (en) | 2019-10-01 | 2022-06-01 | Empyrean Neuroscience Inc | Genetic engineering of fungi to modulate tryptamine expression |
EP4061359A4 (en) | 2019-11-19 | 2024-04-17 | Turtle Bear Holdings, LLC | TRYPTAMIN COMPOSITIONS TO INCREASE NEURIT OUTGROUP |
KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
WO2022047580A1 (en) * | 2020-09-01 | 2022-03-10 | Magicmed Industries Inc. | Hydroxylated psilocybin derivatives and methods of using |
CN112138028A (zh) * | 2020-10-10 | 2020-12-29 | 南京中医药大学 | 蟾蜍色胺类物质在制备抗抑郁药物中的应用 |
CN114870018A (zh) * | 2022-05-12 | 2022-08-09 | 江南大学 | 炎症小体nlrp3抑制剂通过抑制神经***炎症在制备治疗阿尔茨海默症药物中的应用 |
CN115813918B (zh) * | 2022-09-30 | 2024-04-02 | 中国药科大学 | 吲哚乙酸在制备抑郁症治疗药物中的应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA957281A (en) * | 1970-02-03 | 1974-11-05 | Nathan N. Share | Pharmaceutical compositions containing indole-3-acetic acid derivatives as a skeletal muscle stimulant |
US4025650A (en) | 1975-11-24 | 1977-05-24 | Control Drug, Inc. | Method and composition for preventing nutritional deficiency |
GB1475861A (en) | 1976-03-19 | 1977-06-10 | Warner Lambert Co | Pharmaceutical composition |
GB1535778A (en) | 1976-12-06 | 1978-12-13 | Mac Sweeney D | Compounds useful in treatment of unipolar depression |
JPS60199801A (ja) | 1984-03-24 | 1985-10-09 | Masaki Kamata | 動物に対する植物成長ホルモンの投与方法 |
US4687763A (en) | 1985-02-25 | 1987-08-18 | Massachusetts Institute Of Technology | Composition and method for increasing levels or release of brain serotonin |
US4650789A (en) * | 1985-10-15 | 1987-03-17 | Commonwealth Medical Corporation Of America | Method and composition for increasing production of serotonin |
BE1000990A3 (nl) | 1987-10-09 | 1989-05-30 | Picanol Nv | Inrichting voor het op elkaar aansluiten van onderling verplaatsbare elementen, en transportinrichting die eerstgenoemde inrichting toepast. |
GB8727099D0 (en) | 1987-11-19 | 1987-12-23 | Cellena Cell Eng A G | Compositions containing melantonin/homologues |
US4945103A (en) | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
IT1237472B (it) * | 1989-10-04 | 1993-06-07 | Polifarma Spa | Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico. |
US5132113A (en) * | 1990-10-26 | 1992-07-21 | Maurizio Luca | Nutritional composition containing essential amino acids |
US5192753A (en) | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
WO1993007870A1 (en) | 1991-10-18 | 1993-04-29 | Alza Corporation | Device for the transdermal administration of melatonin |
GB9214419D0 (en) | 1992-07-07 | 1992-08-19 | Concannon Peter | Biocidal agents |
JPH0725838A (ja) * | 1993-05-13 | 1995-01-27 | Yotsuba Yuka Kk | 疲労の予防または回復のための経口投与剤 |
JP3541969B2 (ja) | 1994-09-29 | 2004-07-14 | 東洋紡績株式会社 | ベットマット |
JP3617102B2 (ja) | 1995-01-27 | 2005-02-02 | 味の素株式会社 | ヒト筋肉疲労の早期回復効果を有するアミノ酸栄養組成物 |
JPH08308580A (ja) * | 1995-05-17 | 1996-11-26 | Takeda Chem Ind Ltd | 組換え型ヒトghrhレセプター蛋白質、その製造法および用途 |
EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
FR2741799B1 (fr) * | 1995-12-04 | 1998-01-02 | Oreal | Utilisation de melatonine dans une composition pour traiter les signes cutanes des etats de fatigue |
WO1997025060A1 (fr) * | 1996-01-09 | 1997-07-17 | The Institute Of Physical And Chemical Research | Compositions d'acides amines |
FR2746313B1 (fr) | 1996-03-22 | 1998-04-17 | Adir | Utilisation de la melatonine et des ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention et au traitement du diabete et des complications diabetiques |
US5958964A (en) | 1997-02-18 | 1999-09-28 | South Alabama Medical Science Foundation | Use of melatonin to prevent cytotoxic effects of amyloid beta protein |
DE19739763A1 (de) | 1997-09-10 | 1999-09-23 | Franz Uhl | Vitamin B3/Niacin zur Behandlung von Krankheiten |
US6017946A (en) * | 1997-10-08 | 2000-01-25 | Posner; Robert | Serotonin containing formulation for oral administration and method of use |
WO2000009537A2 (en) | 1998-08-14 | 2000-02-24 | Administrators Of The Tulane Educational Fund | Compounds having growth hormone releasing activity |
CA2343214A1 (en) * | 1998-09-03 | 2000-03-16 | Chris Edward Williams | Neuroprotection |
IL132366A0 (en) | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
CN1069050C (zh) | 1998-12-01 | 2001-08-01 | 周旭生 | 一种治疗糖尿病的中药复方制剂 |
EP1135123B1 (en) * | 1998-12-04 | 2004-12-29 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
FR2795323B1 (fr) | 1999-06-23 | 2001-11-16 | Adir | Utilisation de ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention ou au traitement des pathologies du systeme gastrointestinal |
CN1088597C (zh) * | 1999-10-26 | 2002-08-07 | 合肥永生制药有限公司 | 尿多酸肽组合物及其用途 |
US20020155163A1 (en) | 1999-12-27 | 2002-10-24 | Samuel D. Benjamin | Integrated multi-vitamin and mineral combination |
US6521659B2 (en) * | 2000-03-02 | 2003-02-18 | Institute For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
DE10037773C1 (de) * | 2000-08-03 | 2002-08-22 | Hennecke Gmbh | Verfahren und Vorrichtung zum Herstellen von mit Langfasern verstärkten Kunststoff-Formteilen |
DE10109798A1 (de) | 2001-03-01 | 2002-09-12 | Aventis Pharma Gmbh | Gesundheitsfördernde Zusammensetzung von Verbindungen |
US20030166554A1 (en) * | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
JP2002281914A (ja) * | 2001-03-27 | 2002-10-02 | Nishi Nippon Green Kk | 魚類、家畜類の栄養活力促進剤の製造方法 |
US20020147155A1 (en) | 2001-04-06 | 2002-10-10 | Foster Warren G. | Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands |
CN1408397A (zh) | 2001-09-26 | 2003-04-09 | 北京本元青阳生物科技发展有限公司 | 含褪黑素和益智中药的组合物 |
JP2003137808A (ja) * | 2001-10-26 | 2003-05-14 | Kakunai Juyotai Kenkyusho:Kk | 新規経腸栄養剤の製造法 |
CA2479671A1 (en) * | 2002-03-18 | 2003-10-02 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and nicotinic acid for a nicotinic acid derivative |
CN1440744A (zh) | 2003-02-15 | 2003-09-10 | 高景曦 | 纳米包覆退黑激素复合保健品 |
WO2004098498A2 (en) | 2003-04-28 | 2004-11-18 | Bayer Pharmaceuticals Corporation | Indole acetic acid derivatives and their use as pharmaceutical agents |
DK1670444T3 (da) | 2003-10-03 | 2011-08-22 | Veijlen N V | Anvendelse af IFG-1-serumniveau forhøjende indoleddikesyrederivater til fremstilling af en lægemiddelsammensætning til behandling af forskellige sygdomme |
DK1667678T3 (da) | 2003-10-03 | 2009-08-24 | Veijlen N V | Dyrefodersammensætning |
-
2003
- 2003-10-03 DK DK03757934.9T patent/DK1670444T3/da active
- 2003-10-03 SI SI200332019T patent/SI1670444T1/sl unknown
- 2003-10-03 PT PT03757934T patent/PT1670444E/pt unknown
- 2003-10-03 US US10/574,467 patent/US9408405B2/en active Active
- 2003-10-03 DE DE60336934T patent/DE60336934D1/de not_active Expired - Lifetime
- 2003-10-03 EP EP03757934A patent/EP1670444B1/en not_active Expired - Lifetime
- 2003-10-03 JP JP2005509805A patent/JP4641942B2/ja not_active Expired - Fee Related
- 2003-10-03 WO PCT/EP2003/011171 patent/WO2005039546A2/en active Application Filing
- 2003-10-03 CN CN2003801105778A patent/CN1938018B/zh not_active Expired - Fee Related
- 2003-10-03 CA CA2541090A patent/CA2541090C/en not_active Expired - Lifetime
- 2003-10-03 AT AT03757934T patent/ATE506948T1/de active
- 2003-10-03 ES ES03757934T patent/ES2365847T3/es not_active Expired - Lifetime
- 2003-10-03 AU AU2003273967A patent/AU2003273967A1/en not_active Abandoned
-
2004
- 2004-09-28 ES ES04765746T patent/ES2326595T3/es active Active
- 2004-09-28 RU RU2006114743/13A patent/RU2345552C2/ru active
- 2004-09-28 PT PT04765746T patent/PT1667678E/pt unknown
-
2007
- 2007-07-27 HK HK07108228.0A patent/HK1103963A1/xx not_active IP Right Cessation
-
2011
- 2011-07-26 CY CY20111100732T patent/CY1116665T1/el unknown
-
2016
- 2016-07-06 US US15/203,671 patent/US10716778B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10716778B2 (en) | 2003-10-03 | 2020-07-21 | Veijlen | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals |
Also Published As
Publication number | Publication date |
---|---|
HK1103963A1 (en) | 2008-01-04 |
CN1938018A (zh) | 2007-03-28 |
US9408405B2 (en) | 2016-08-09 |
CA2541090C (en) | 2013-04-16 |
PT1667678E (pt) | 2009-08-05 |
CN1938018B (zh) | 2010-09-01 |
US20160331725A1 (en) | 2016-11-17 |
PT1670444E (pt) | 2011-07-29 |
JP4641942B2 (ja) | 2011-03-02 |
US10716778B2 (en) | 2020-07-21 |
WO2005039546A2 (en) | 2005-05-06 |
ES2365847T3 (es) | 2011-10-11 |
JP2007525405A (ja) | 2007-09-06 |
AU2003273967A8 (en) | 2005-05-11 |
SI1670444T1 (sl) | 2011-09-30 |
ATE506948T1 (de) | 2011-05-15 |
EP1670444A2 (en) | 2006-06-21 |
WO2005039546A3 (en) | 2007-10-04 |
DK1670444T3 (da) | 2011-08-22 |
CY1116665T1 (el) | 2017-03-15 |
AU2003273967A1 (en) | 2005-05-11 |
RU2345552C2 (ru) | 2009-02-10 |
DE60336934D1 (de) | 2011-06-09 |
CA2541090A1 (en) | 2005-05-06 |
EP1670444B1 (en) | 2011-04-27 |
ES2326595T3 (es) | 2009-10-15 |
US20080194553A1 (en) | 2008-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006114743A (ru) | Композиция корма для животных | |
CN1026064C (zh) | 活性氧抑制组合物的制造方法 | |
CN1065438C (zh) | 环状粘着抑制剂 | |
CN1054040C (zh) | 载有喹诺酮羧酸衍生物的离子交换树酯的制备 | |
CN1117874A (zh) | 经鼻给药组合物 | |
CN86100757A (zh) | 改进或有关增加动物饲料摄取量的方法 | |
CN86106150A (zh) | 可嚼胶囊 | |
CN86105023A (zh) | 延长生长促进激素的释放 | |
JP5477997B2 (ja) | ビタミンd化合物の使用 | |
CN105999231B (zh) | 一种多肽组合物、提高畜禽免疫功能的组合物、制备方法 | |
JP2007507213A5 (ru) | ||
CN1041107A (zh) | 促进猪生长的方法 | |
JPS6089488A (ja) | 新規アミノ酸誘導体の製法 | |
CN1341591A (zh) | 四水合n-[邻-(对-三甲基乙酰氧基苯磺酰胺基)苯甲酰基]甘氨酸单钠盐的溶液及其药品 | |
CN1566086A (zh) | 一种氨基酸螯合钙及其制剂和应用 | |
CN1129452C (zh) | 表皮生长因子***片 | |
JPH0651628B2 (ja) | 栄養剤組成物 | |
CN112472714B (zh) | 一种含硝酸盐的组合物及其应用 | |
CN1264552C (zh) | 一种预防骨质疏松和延缓衰老的制剂及其制备方法 | |
RU2294196C2 (ru) | Лечебно-кормовая добавка и способ ее применения при паразитозах животных | |
RU2067445C1 (ru) | Препарат "полифар" для лечения желудочно-кишечных болезней новорожденных телят | |
RU2185836C2 (ru) | Витаминный препарат "апилактин" | |
RU2096970C1 (ru) | Премикс для свиней "айболит" | |
CN1259105C (zh) | 重组人干扰素α2b含片及其制备方法 | |
JPH05310563A (ja) | カルシトニン産生増強剤 |